Roche Holding AG Basel American Depositary Shares (RHHBY)
$33.81
0.25 (0.74%)
RHHBY Stock Quote Delayed 30 Minutes
11 Best Stocks to Buy for 2023
INSIDE: Investing legend Louis Navellier reveals his Top 11 Stocks for 2023 — FREE!
Download His Free Report Here:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Unlock Louis Navellier's
? Stock Report – FREE:
Is ? a BUY?
Powered by Portfolio Grader
A
B
C
D
F
?
Unlock Louis Navellier's
? Stock Report to Find Out – FREE:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Investing legend Louis Navellier rates ? a "?." Unlock his ? Stock Analysis to find out why – FREE:
Louis Navellier's Total Grade
Powered by Portfolio Grader?
Fundamental Grade
Quantitative Grade
- Sales Growth ?
- Operating Margin Growth ?
- Earnings Growth ?
- Earnings Momentum ?
- Earnings Surprises ?
- Analyst Earnings Revisions ?
- Cash Flow ?
- Return on Equity ?
Previous Close
-
Market Cap
-
PE Ratio
-
EPS
-
Volume (Avg. Vol.)
2.16M
Day's Range
$33.65 - $33.85
52-Week Range
$27.95 - $41.71
Dividend & Yield
N/A (N/A)
RHHBY Stock Predictions, Articles, and Roche Holding AG Basel American Depositary Shares News
Roche Stock Rallies on Promising Coronavirus Drug Results
Roche stock is rallying Friday on news that Actemra, an anti-inflammatory drug from the Swiss company, may help coronavirus patients.
Roche Holding News: RHHBY Stock Jumps 8% on Faster Coronavirus Test
Roche Holding (RHHBY) news for Friday includes an update on testing for the coronavirus from China with approval from the FDA.
Why NewLink Genetics Corp (NLNK), Urban Outfitters, Inc. (URBN) and Dell Technologies Inc (DVMT) Are 3 of Today’s Worst Stocks
Dell Technologies (DVMT), NewLink Genetics (NLNK) and Urban Outfitters (URBN) shareholders couldn't wait for Thursday's action to come to a close.
3 Cheap Biotech Stocks The Big Boys Are Buying (BLRX, OMED, FWP)
Biotechnology is among the most exciting and lucrative sectors for investors, and these 3 biotech stocks stand out...
iShares MSCI EAFE Index Fund (ETF) (EFA): The Quick Guide to EFA
The iShares MSCI EAFE ETF (EFA) holds nearly 940 stocks based outside the U.S. Is the EFA the right way to get international exposure?
Here’s How You Can Invest In The World’s Most Innovative Country: Switzerland (EWL)
I've uncovered a data set that show Switzerland as the most innovative country in the world. Here's how to take advantage...
Roche Holding Ltd. (ADR) (RHHBY) Stock Is Weathering the Healthcare Storm
Roche has plenty of great drugs under its umbrella and RHHBY stock should do well no matter what the government decides to do.
Roche Holding Ltd. (RHHBY) Still Has a Few Tricks Up its Sleeve
The Big Pharma is set to have a very good 2017 and put 2016 behind it.
How Big Data & Big Pharma Will Transform Drug Development
Big data can be used by big pharma companies like Roche to drastically cut costs, increase drug production and drive long-term stock gains.
U.S. Debut of Biosimilar Drugs Threatens Major Biotechs
The introduction of biosimilar drugs will change the biotech landscape ... especially for these three names.
Add Roche to Your List of Ebola Stocks, But …
Ebola stocks have doled out some big gains to savvy traders this year, but investors looking for Roche (RHHBY) to do the same may want to rethink their expectations.
Gilead Stock Will Rise on Sovaldi® Sales
Gilead's breakthrough Hepatitis C drug, Sovaldi®, will drive revenue and profits for the rest of 2014 and into 2015.
Roche Proves You Can’t Judge a Book by Its Cover
Roche stock may not be an NYSE or NASDAQ-listed equity, but when you look at the details, RHHBY is plenty investment-worthy.
3 Huge Healthcare Trends Can Fatten Your Portfolio
Healthcare concerns in the U.S. are being addressed by companies in the industry. These 3 issues can lead investors to stock opportunities
Our Stock Earnings Rundown – HSY KMB DFS SHW LUV TMO AMGN
A big week for earnings and dividend increases includes these 8 stocks in our portfolio.
Roche’s Breast Cancer Drug Approval Is Just the Beginning
It might have been dismissed as irrelevant by most investors, but Roche and its Perjeta could reshape the breast cancer drug landscape.
